New hope for brain tumor patients: drug combo enters trials
NCT ID NCT06478212
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This study tests a new drug, vorasidenib, combined with a standard chemotherapy (temozolomide) in people with a specific type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to find the safest dose and see if the combination can help control the tumor. About 51 participants aged 12 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTANT GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, 100050, China
-
Christie Hospital
Manchester, M20 4BX, United Kingdom
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Erasmus MC
Rotterdam, 503015, Netherlands
-
H. Valle de Hebron
Barcelona, 08035, Spain
-
Hospital 12 de Octubre
Madrid, 28041, Spain
-
Huashan Hospital, Fudan University
Shanghai, 200040, China
-
Hôpital Pierre Wertheimer
Lyon, 69003, France
-
Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
IOV - Ospedale Busonera
Padua, 35128, Italy
-
IUCT-Oncopole Institut Universitaire du Cancer
Toulouse, 31059, France
-
Instituto Clinico Humanitas IRCCS
Rozzano, Milan, 20089, Italy
-
Kumamoto University Hospital
Kumamoto, 860-8556, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Vienna - AKH
Vienna, 01090, Austria
-
Medizinische Fakultät Mannheim, Universität Heidelberg
Mannheim, 68167, Germany
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nagoya University Hospital
Nagoya, 466-8550, Japan
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
Ospedale Molinette - Centro Oncologico Ematologico
Turin, 10126, Italy
-
The Royal Marsden in Sutton
Sutton, SM2 5PT, United Kingdom
-
The Tel Aviv Sourasky Medical Center (TASMC) (Ichilov Hospital)
Tel Aviv, 64239, Israel
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Regensburg
Regensburg, 93053, Germany
Conditions
Explore the condition pages connected to this study.